Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|February 9, 2022

INSPIRE and IMvigor011 Trials

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

Episodes in this series

EP. 1 Explaining Molecular Residual Disease

EP. 1 Explaining Molecular Residual Disease

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 3 MRD Assessments

EP. 3 MRD Assessments

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 5 MRD and Value-Based Care Models

EP. 5 MRD and Value-Based Care Models

EP. 6 Supporting MRD Availability

EP. 6 Supporting MRD Availability

EP. 7 INSPIRE and IMvigor011 Trials

EP. 7 INSPIRE and IMvigor011 Trials

EP. 8 Potential Changes for MRD in the Future

EP. 8 Potential Changes for MRD in the Future

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Anita Kumar, MD, of MSKCC in Basking Ridge, New Jersey, highlighted advances in treatment of transplant-ineligible mantle cell lymphoma, including chemotherapy-free options. | Image: MSKCC

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

June 20th 2026

Myeloproliferativedisorder | Image Credit: © ibreakstock-stock.adobe.com

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

ByMaggie L. Shaw

June 19th 2026

Principal investigator Sara A. Hurvitz, MD, said results with the gedatolisib combinations show they could be the new standard of care in HR+/HER2- advanced breast cancer. | Image: Fred Hutch

In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer

June 19th 2026

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 19th 2026

Fibrosis Belongs at Center of MASH End Points: Zobair M. Younossi, MD

ByLaura Joszt, MA,Zobair M. Younossi, MD

June 19th 2026

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Defunding Co-Payment Assistance Disrupted nAMD Care

Aficamten Outperforms Metoprolol Across All Phases of Exercise in Obstructive HCM